Institutional and Insider Ownership
0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Evofem Biosciences and Panbela Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evofem Biosciences | $11.39 million | 0.12 | $52.98 million | ($0.06) | -0.18 |
| Panbela Therapeutics | N/A | N/A | -$25.26 million | ($71.13) | 0.00 |
Risk and Volatility
Evofem Biosciences has a beta of -1.28, indicating that its stock price is 228% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
Profitability
This table compares Evofem Biosciences and Panbela Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evofem Biosciences | -46.42% | -91.97% | -61.93% |
| Panbela Therapeutics | N/A | N/A | -302.61% |
Summary
Panbela Therapeutics beats Evofem Biosciences on 5 of the 9 factors compared between the two stocks.
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
About Panbela Therapeutics
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
